CXCR4 and neoplasm: Intraperitoneal administration of LY364947 (25 mg/kg), a TGF‐β receptor inhibitor, to LLC1 tumor‐bearing mice decreased Cxcr4 mRNA and protein expression levels in tumor‐infiltrated CD8+ T cells (Figure 4A,B).